Summit Therapeutics flags OS superiority for ivonescimab Phase III
TradingView News reports Summit Therapeutics says its ivonescimab regimen shows OS superiority in Phase III HARMONi-GI1.
Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
1 result loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
TradingView News reports Summit Therapeutics says its ivonescimab regimen shows OS superiority in Phase III HARMONi-GI1.